Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LBx-PA01
- Development stage
- Discontinued
- Lead developer
- Locus Biosciences
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Gene Therapies
01
Overview
LBx-PA01 is an investigational CRISPR-Cas3–enhanced bacteriophage antimicrobial being developed by Locus Biosciences as a precision therapy targeting Pseudomonas aeruginosa, including multidrug-resistant strains that are a serious hospital-acquired infection threat. It consists of engineered bacteriophages programmed with guide RNAs to direct the Cas3 nuclease to P. aeruginosa DNA, causing extensive, irreversible genome degradation in addition to the natural lytic activity of the phages, thereby selectively killing the pathogen while sparing non-target bacteria.[5][6] The program was supported by a partnership with IDbyDNA to develop a metagenomic companion diagnostic (based on the Explify platform) to identify P. aeruginosa–infected patients most likely to benefit from LBx-PA01 in clinical trials.[5][6][10][13]
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on LBx-PA01.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LBx-PA01.